Pharmaceutical

Insmed’s gene therapy poised to challenge DMD landscape after IND clearance

Insmed is set to challenge the Duchenne muscular dystrophy (DMD) treatment space with its innovative gene therapy asset, INS1201.

Jan 16, 2025 - 06:00
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance
Insmed is set to challenge the Duchenne muscular dystrophy (DMD) treatment space with its innovative gene therapy asset, INS1201.
Read the original article

Tags:

Previous Article

JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead

Next Article

AbbVie and Simcere Zaiming link to develop trispecific antibody

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Appeals court rules Purdue can shield Sacklers from lawsuits; chemo shortage blamed on drugmakers’ lack of investment

STAT+: Pharmalittle: Appeals court rules Purdue can shi...

May 31, 2023

STAT+: Listen: Is the Nobel committee evolving? Plus, preventing public health’s wiliest virus

STAT+: Listen: Is the Nobel committee evolving? Plus, p...

Oct 8, 2023

Don’t ignore potential microbial causes of Alzheimer’s and other chronic diseases, researchers say

Don’t ignore potential microbial causes of Alzheimer’s ...

May 3, 2023